Milestone Announces PSVT Registry Amid Critical Launch Phase

What happened

Milestone Pharmaceuticals is in the early commercial phase of launching CARDAMYST, its self-administered nasal spray for PSVT, following FDA approval in December 2025. The company has announced the RESET-PSVT registry, aimed at generating real-world evidence on CARDAMYST's use in PSVT patients, as presented at a nursing symposium. This move comes as MIST faces investor scrutiny over the lack of disclosed prescription data and payer coverage breadth, key gating variables highlighted in recent reports. While the registry could help build clinical support and potentially aid in payer negotiations, it does not directly address the immediate need for quantitative TRx/NRx metrics or additional PBM wins. Therefore, the announcement is more about long-term evidence generation rather than a near-term catalyst for the commercial launch.

Implication

In the short term, the registry is unlikely to impact sales or access, as it focuses on data collection rather than immediate commercial execution. Investors should view this as part of MIST's efforts to strengthen the product's clinical profile, which could support future formulary decisions and prescriber adoption. However, the critical investment thesis remains unchanged, centered on the disclosure of prescription metrics and payer coverage by mid-2026. Failure to provide such quantitative updates could signal ongoing launch challenges, overshadowing any registry-based initiatives. Thus, while the registry adds to the long-term evidence base, it does not reduce the risk associated with the current 'prove-it' phase of commercialization.

Thesis delta

The launch thesis for MIST remains focused on observable script growth and payer access expansion by Q2 2026. The RESET-PSVT registry, while supportive of long-term data needs, does not shift this timeline or address the immediate proof points required for conviction, so no material change to the investment call is warranted.